Please select the option that best describes you:
Would you offer consolidative radiotherapy for oligometastatic NSCLC?
Given that LU002 has failed to meet its progression free survival benefit in results presented at ASCO, will you offer consolidative radiotherapy for oligometastatic NSCLC?
Answer from: Radiation Oncologist at Community Practice
These are extremely challenging cases and the recent negative studies have somewhat dampened my enthusiasm. It has been challenging, in general, to obtain authorization for treatment in these cases and the release of this data will not make it any easier.
And as experts note, there are multip...
Sign in or Register to read more